Updated March 8, 2026 by Theresa Vuskovich, DMD. To give you technically accurate, evidence-based information, content published on the Everlywell blog is reviewed by credentialed professionals with expertise in medical and bioscience fields.
Everlywell works with preferred partners. If you click on links or make a purchase through this page, we may earn a commission.
Table of contents
- What Is Semaglutide?
- What Are the Brand Names of Semaglutide?
- What Brand of Semaglutide Is the Best for Non-Diabetics?
- What Are the Risks of Semaglutide?
- How Long Will Semaglutide Weight Loss Results Last?
- Exploring Treatment Options
- Related Content
The obesity epidemic continues to affect millions of Americans, with approximately two-thirds of the population classified as overweight or obese.[1] Individuals who are overweight or have obesity are more likely to develop type 2 diabetes (T2D), though not everyone with excess weight develops the condition.[2]
For non-diabetics seeking support with weight loss, semaglutide has gained significant attention. Originally developed to treat diabetes, semaglutide has also been shown to support meaningful weight loss in some individuals without diabetes.[3,4] This article explains how semaglutide works for weight loss in non-diabetics and what to consider before starting treatment.
What Is Semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist designed to bind to GLP-1 receptors, which help regulate appetite.[4] Semaglutide was originally developed as a treatment for T2D to improve blood sugar levels, but clinical trials later showed that patients also lost weight while taking it.[4-8] Additional studies support semaglutide’s effectiveness in promoting weight loss in non-diabetics.[5,8,11]
Semaglutide supports weight loss by suppressing appetite, delaying stomach emptying, and stimulating insulin secretion.[4] It is typically used alongside dietary changes and exercise in adults with and without diabetes.[4] All GLP-1 medications require a prescription from a healthcare provider.
In addition to its role in weight loss and blood sugar control, semaglutide may also help reduce the risk of cardiovascular events in adults with T2D and a history of heart disease. During the SUSTAIN 6 clinical trial, semaglutide significantly reduced the risk of major cardiovascular events.[6]
What Are the Brand Names of Semaglutide?
Semaglutide is the active ingredient in three popular medications: Wegovy®, Ozempic®, and Rybelsus®.[5-7] While all three contain semaglutide, only Wegovy® is approved by the U.S. Food and Drug Administration (FDA) for weight loss.[5] A healthy diet and regular exercise are recommended to help optimize the benefits of semaglutide.[5-7]
Here is a closer look at the different brands of semaglutide:[5-11]
- Wegovy®: Wegovy® is a once-weekly subcutaneous injection delivered in a prefilled, single-dose pen. It is indicated for adults with obesity (BMI of 30 kg/m^2 or greater) and adults who are overweight (BMI of 27 kg/m^2 or greater) with at least one weight-related medical condition, such as high blood pressure, T2D, or dyslipidemia. In clinical trials, 86% of non-diabetic patients receiving once-weekly semaglutide injections lost at least 5% of their body weight.[8]
- Ozempic®: Ozempic® is a once-weekly subcutaneous injection approved for patients with T2D, though it is sometimes prescribed off-label for weight loss.[9] It is used alongside diet and exercise to improve glycemic control and reduce cardiovascular risk in adults with T2D.
- Rybelsus®: Rybelsus® is the oral version of semaglutide and the first GLP-1 pill. It is approved to improve blood sugar levels in adults with T2D and is taken once daily with diet and exercise. In some cases, it may also be prescribed off-label for weight management in people without diabetes.[9]
What Brand of Semaglutide Is the Best for Non-Diabetics?
Your healthcare provider will help determine which brand of semaglutide may be most appropriate for you. Wegovy® is the only semaglutide medication approved by the FDA specifically for weight loss.[3] However, Ozempic® and Rybelsus® are sometimes prescribed off-label for weight management. According to the FDA, healthcare providers may prescribe a drug for an unapproved use if they determine it is medically appropriate.[9]
What Are the Risks of Semaglutide?
The most common adverse reactions reported in patients treated with semaglutide include nausea, vomiting, diarrhea, abdominal pain, and constipation.[5-7] Semaglutide may also increase the risk of pancreatitis, acute gallbladder disease, hypersensitivity reactions, acute kidney injury, and thyroid C-cell tumors.[5-7]
Whether semaglutide is safe in people with pancreatitis remains unclear.[5-7] It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).[5-7]
How Long Will Semaglutide Weight Loss Results Last?
How long semaglutide weight loss results last depends on a range of factors, including long-term lifestyle habits. One clinical trial found that participants regained about two-thirds of their previously lost weight within one year of stopping subcutaneous semaglutide.[10]
Maintaining a relationship with a healthcare provider may help support long-term success by offering guidance, monitoring progress, and helping you build sustainable habits.
Exploring Treatment Options
Semaglutide may be an option for some non-diabetics seeking medical support for weight loss, but the best treatment approach depends on your health history, goals, and eligibility. Working with a licensed healthcare provider can help you understand the differences between semaglutide medications and determine whether treatment may be appropriate for you.
Some individuals choose to explore telehealth weight management programs that connect patients with licensed providers who can evaluate eligibility for medications like semaglutide and help create a personalized treatment plan.
Related Content
How to Keep the Weight Off After Semaglutide
How Much Weight Can You Lose On Semaglutide?
References
- Overweight & obesity statistics. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/health-statistics/overweight-obesity Published September 16, 2022. Accessed May 8, 2023.
- Nianogo RA, Arah OA. Forecasting obesity and type 2 diabetes incidence and burden: The ViLA-obesity simulation model. Front Public Health. 2022;10:818816. doi:10.3389/fpubh.2022.818816. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016163/
- Phillips A, Clements JN. Clinical review of subcutaneous semaglutide for obesity. Journal of Clinical Pharmacy and Therapeutics. 2022;47(2):184-193. doi:10.1111/jcpt.13574. https://onlinelibrary.wiley.com/doi/10.1111/jcpt.13574
- Latif W, Lambrinos KJ, Rodriguez R. Compare And Contrast the Glucagon-like Peptide-1 Receptor Agonists (GLP1RAs). StatPearls Publishing; 2022. https://www.ncbi.nlm.nih.gov/books/NBK572151/
- Wegovy® Prescribing Information. Novo-pi.com. https://www.novo-pi.com/wegovy.pdf. Accessed April 20, 2023.
- Ozempic® Prescribing Information. Novo-pi.com. https://www.novo-pi.com/ozempic.pdf. Accessed April 20, 2023.
- Rybelsus® Prescribing Information. Novo-pi.com. https://www.novo-pi.com/rybelsus.pdf. Accessed May 6, 2023.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- Understanding Unapproved Use of Approved Drugs “Off Label.” U.S. Food and Drug Administration. https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label. Accessed May 8, 2023.
- Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, Mcgowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity, and Metabolism. 2022;24(8):1553-1564. doi:10.1111/dom.14725. https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14725
- Gao X, Hua X, Wang X, et al. Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2022;13:935823. doi:10.3389/fphar.2022.935823. https://www.frontiersin.org/articles/10.3389/fphar.2022.935823/full
Spotlight on
Featured content
Explore Everlywell
